Navigation Links
Actos Caused Bladder Cancer and Wrongful Death of New York Woman, Alleges Lawsuit Filed by Parker Waichman LLP
Date:7/9/2013

New York, New York (PRWEB) July 09, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Actos is to blame for the bladder cancer and subsequent wrongful death of a New York woman. The suit was filed on May 23, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-1239). It is one of thousands of cases that have been filed as part of the multidistrict litigation (MDL) entitled In Re: Actos (pioglitazone) Products Liability Litigation (6:11-md-2299). Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants. Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation.

According to the Complaint, the Plaintiff’s Decedent started taking Actos in 2001. The Decedent was diagnosed with bladder cancer in December 2008 and subsequently died in June 2012, allegedly because of Actos’ side effects. The lawsuit alleges that the Decedent suffered from extensive pain and suffering and severe emotional distress as a result of using Actos. The drug also allegedly reduced the Decedent’s ability to enjoy life.

The U.S. Food and Drug Administration (FDA) has warned about the risks of taking Actos. In June 2011, the agency said that taking Actos for more than a year could significantly increase the risk of bladder cancer. The safety label on Actos was updated to address this risk.

Some research studies support the notion of a link between Actos and bladder cancer. The British Medical Journal published a study on May 31, 2012, that revealed Actos users were twice as likely to develop bladder cancer after two years. Then, on July 3, 2012, the Canadian Medical Association Journal reported that patients taking the medication were 22 percent more likely to get bladder cancer.

Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/072013/prweb10912790.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Florida Man Develops Bladder Cancer as Result of Taking Actos, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Recent Status Conference in Federal Actos Bladder Cancer Litigation
3. Actos Lawsuit News: Plaintiff Claims Actos Causes Bladder Cancer, Rottenstein Law Group LLP Reports
4. Lawsuit Alleging Actos Caused Arizona Man’s Bladder Cancer Filed by Parker Waichman LLP
5. Buckfire & Buckfire, P.C. Dangerous Drug Lawyers Now Accepting Michigan Actos Lawsuits
6. Actos Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Actos Bladder Cancer Litigation
7. Parker Waichman LLP Represents Pennsylvania Man in Lawsuit Alleging Actos Caused his Bladder Cancer
8. Actos Lawsuits: Bernstein Liebhard LLP Notes More Than 1,500 Cases Now Filed in Federal Litigation
9. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Actos Bladder Cancer Litigation
10. Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation
11. Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Dr. David Mahon leads Siena Dental, a ... Mahon was named a 2017 Top Patient Rated Henderson Dentist by Find ... that recognizes local physicians and dentists who have earned high ratings and superior patient ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism ... Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly ... (ASD) to see films in an environment that accommodates their unique needs. , ...
(Date:2/23/2017)... ... 23, 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior ... to the Minneapolis Home and Garden Show which is being held February 24 through ... attention is the Minneapolis Convention Center. , From its broad line of sit ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Gevir, a New ... antler velvet, announced its products are coming soon to Amazon.com, the world’s largest online ... Thomson as a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, ...
(Date:2/22/2017)... ... 22, 2017 , ... South Bend’s Lunkerville, the award-winning TV series that catches ... The Water (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and ... D’ traveling to Lake Denmark, New Jersey, to fish with war veteran Justin Vail ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... Mass. , Feb. 23, 2017   ... partner to global in vitro diagnostics manufacturers and ... series titled "Catalyzing Implementation of NGS-Based Tests" to ... March 30, 2017 at 11am Eastern Standard Time ... is to highlight the need for improved performance ...
(Date:2/23/2017)... MabVax Therapeutics Holdings, Inc . ... announces that it has received notice from the ... initiation a Phase I clinical trial with MVT-1075 ... ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel fully ... the phase I clinical trial in patients with ...
Breaking Medicine Technology: